NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Forecast, Price & News Notice: Trading of Enveric Biosciences halted at 09:37 AM EST due to "LULD pause". $3.59 +2.07 (+136.18%) (As of 05/18/2023 ET) Add Compare Share Share Today's Range$2.02▼$4.4950-Day Range$1.33▼$2.0652-Week Range$1.30▼$18.50Volume119.39 million shsAverage Volume1.30 million shsMarket Capitalization$7.47 millionP/E RatioN/ADividend YieldN/APrice Target$43.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Enveric Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,118.7% Upside$43.75 Price TargetShort InterestHealthy1.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.75, Enveric Biosciences has a forecasted upside of 1,118.7% from its current price of $3.59.Amount of Analyst CoverageEnveric Biosciences has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.75% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently increased by 44.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENVB. Previous Next 2.3 News and Social Media Coverage News SentimentEnveric Biosciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Enveric Biosciences this week, compared to 0 articles on an average week.Search Interest7 people have searched for ENVB on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.97% of the stock of Enveric Biosciences is held by insiders.Percentage Held by InstitutionsOnly 13.40% of the stock of Enveric Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enveric Biosciences (NASDAQ:ENVB) StockEnveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.Read More Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENVB Stock News HeadlinesMay 18, 2023 | msn.comEnveric Bio Stock Spikes 115% After Its Novel Prodrug Of Psilocin Receives Notice Of Allowance From US Patent And Trademark OfficeMay 18, 2023 | theglobeandmail.comEnveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373May 18, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 18, 2023 | msn.comEnveric Skyrockets on Bagging Notice of Allowance from USPTO for Lead CandidateMay 18, 2023 | finance.yahoo.comEnveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of PsilocinMay 15, 2023 | msn.comEnveric Biosciences Q1 Net Loss Of $4.80M, More On Basic And Diluted Loss Per ShareApril 14, 2023 | markets.businessinsider.comEXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'April 10, 2023 | finance.yahoo.comEnveric Biosciences to Participate in Benzinga Psychedelics Capital ConferenceMay 18, 2023 | Tradewins (Ad)The Easiest Way To Start Trading OptionsTrading and options expert Chuck Hughes’ new guide reveals the simplest way to begin profitable options trading, even if you have zero experience. And if you download this free guide today, you will also receive a special bonus from Hughes himself. April 3, 2023 | finance.yahoo.comEnveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial ResultsMarch 28, 2023 | americanbankingnews.comEnveric Biosciences (ENVB) Set to Announce Earnings on WednesdayMarch 23, 2023 | finance.yahoo.comEnveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373March 21, 2023 | finance.yahoo.comEnveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health IndicationsMarch 14, 2023 | benzinga.comEnveric Biosciences: Novel Next-Gen Drug Discovery Platform Includes Rare Toad EnzymeFebruary 28, 2023 | finance.yahoo.comEnveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)February 23, 2023 | finance.yahoo.comEnveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)February 22, 2023 | seekingalpha.comENVB Enveric Biosciences, Inc.February 22, 2023 | finance.yahoo.comEnveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth ConferenceFebruary 1, 2023 | finance.yahoo.comEnveric Biosciences to Present at the BIO CEO & Investor ConferenceDecember 21, 2022 | finance.yahoo.comEnveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"November 16, 2022 | finance.yahoo.comEnveric Biosciences to Participate in A.G.P.’s Virtual Biotech ConferenceNovember 1, 2022 | finance.yahoo.comEnveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022October 24, 2022 | finance.yahoo.comEnveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling StudiesOctober 12, 2022 | finance.yahoo.comEnveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders ConferenceAugust 31, 2022 | finance.yahoo.comEnveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022August 10, 2022 | finanznachrichten.deMicrosmallcap.com: Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on DepressionJuly 27, 2022 | uk.investing.comEnveric Biosciences Stock Is Nosediving Today: What's Happening?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENVB Company Calendar Today5/18/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENVB CUSIPN/A CIK890821 Webjaypharma.co Phone(239) 302-1707Fax732-243-9254Employees2Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.75 High Stock Price Forecast$62.50 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+1,293.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($11.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.14% Return on Assets-47.27% Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio4.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.01 per share Price / Book0.63Miscellaneous Outstanding Shares2,080,000Free Float1,975,000Market Cap$6.53 million OptionableNot Optionable Beta1.47 Key ExecutivesJoseph TuckerChief Executive Officer & DirectorAvani V. KanubaddiPresident & Chief Operating OfficerKevin M CoveneyChief Financial OfficerJillian HagelChief Technology OfficerBob DagherChief Medical OfficerKey CompetitorsCNS PharmaceuticalsNASDAQ:CNSPGRI BioNASDAQ:GRINeptune Wellness SolutionsNASDAQ:NEPTHistogenNASDAQ:HSTOAthenexNASDAQ:ATNXView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCBought 26,721 shares on 5/9/2023Ownership: 6.876%View All Institutional Transactions ENVB Stock - Frequently Asked Questions Should I buy or sell Enveric Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENVB shares. View ENVB analyst ratings or view top-rated stocks. What is Enveric Biosciences' stock price forecast for 2023? 1 equities research analysts have issued 1 year price targets for Enveric Biosciences' shares. Their ENVB share price forecasts range from $25.00 to $62.50. On average, they anticipate the company's stock price to reach $43.75 in the next year. This suggests a possible upside of 1,293.3% from the stock's current price. View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts. How have ENVB shares performed in 2023? Enveric Biosciences' stock was trading at $2.08 on January 1st, 2023. Since then, ENVB shares have increased by 51.0% and is now trading at $3.14. View the best growth stocks for 2023 here. Are investors shorting Enveric Biosciences? Enveric Biosciences saw a increase in short interest in April. As of April 30th, there was short interest totaling 32,500 shares, an increase of 44.4% from the April 15th total of 22,500 shares. Based on an average daily trading volume, of 32,200 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.8% of the shares of the company are sold short. View Enveric Biosciences' Short Interest. When is Enveric Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our ENVB earnings forecast. What ETF holds Enveric Biosciences' stock ? AdvisorShares Psychedelics ETF holds 122,429 shares of ENVB stock, representing 2.69% of its portfolio. When did Enveric Biosciences' stock split? Shares of Enveric Biosciences reverse split on the morning of Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is Enveric Biosciences' stock symbol? Enveric Biosciences trades on the NASDAQ under the ticker symbol "ENVB." Who are Enveric Biosciences' major shareholders? Enveric Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include AdvisorShares Investments LLC (6.88%). How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enveric Biosciences' stock price today? One share of ENVB stock can currently be purchased for approximately $3.14. How much money does Enveric Biosciences make? Enveric Biosciences (NASDAQ:ENVB) has a market capitalization of $6.53 million. The company earns $-18,470,000.00 in net income (profit) each year or ($11.39) on an earnings per share basis. How can I contact Enveric Biosciences? Enveric Biosciences' mailing address is 4080 MCGINNIS FERRY ROAD SUITE 1306, ALPHARETTA GA, 30005. The official website for the company is jaypharma.co. The company can be reached via phone at (239) 302-1707, via email at ir@ameri100.com, or via fax at 732-243-9254. This page (NASDAQ:ENVB) was last updated on 5/18/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.